Related Experiment Videos
Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B
P J Hoskins1, V Ng, J J Spinelli
1Division of Medical Oncology and Epidemiology, Cancer Control Agency of British Columbia, Vancouver, Canada.
Summary
This study identified four key factors predicting survival in diffuse large-cell lymphoma patients treated with MACOP-B chemotherapy. A simple formula estimates 5-year survival based on these negative predictors.
Area of Science:
- Oncology
- Hematology
- Clinical Medicine
Background:
- Diffuse large-cell lymphoma (DLCL) is an aggressive non-Hodgkin lymphoma.
- Treatment regimens aim to improve patient survival and outcomes.
- Predictive models are crucial for stratifying patients and tailoring therapy.
Purpose of the Study:
- To identify independent predictors of overall survival in DLCL patients treated with MACOP-B.
- To develop a simple formula for estimating 5-year survival probability.
Main Methods:
- Retrospective analysis of 126 DLCL patients treated with MACOP-B chemotherapy.
- Univariate and multivariate analyses to identify prognostic factors.
- Development of an empirical survival prediction formula.
Main Results:
- Four independent negative predictors of survival were identified: B symptoms, >2 involved lymph node sites, >1 extranodal site, and age >60.
- Each predictor contributed equally to the relative risk of death.
- A formula, (4-N) x 30, was derived to estimate 5-year survival, where N is the number of predictors present.
Conclusions:
- Age, tumor burden (lymph node and extranodal sites), and B symptoms are significant predictors of survival in DLCL.
- The derived formula provides a simple tool for estimating survival probability.
- These predictors remained significant even in patients achieving complete response.